Analyst OutlookAnalyst reiterates a Buy rating with a 12-month $18 price target, signaling continued confidence in potential upside to the company’s valuation.
Commercial Rollout MomentumPharmacy orders for ZUNVEYL have shown strong quarter-over-quarter growth, indicating accelerating commercial adoption and improving demand dynamics.
Contracting And Market AccessAdditional group purchasing organization contracts are likely to be secured, which would broaden institutional access and support a faster sales trajectory.